Gilead Sciences (NASDAQ:GILD) has been no stranger to controversy, with complaints about the pricing of its hepatitis c therapy Sovaldi coming in from every corner. Even with the drug's massive market success so far ($2.3 billion in sales in its first full quarter on the market), pushback from governments and payers has been a continuing concern for the stock.

And now, with France announcing a new information-sharing agreement among 14 EU countries, that pushback just got a little harder. In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take on the news out of Europe.

David Williamson owns shares of Express Scripts. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Express Scripts and Gilead Sciences. The Motley Fool owns shares of Express Scripts and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.